GlassScriptPhysician profile
Frederic L Monosiet
NPI 1528230828
$10,303.98
in general payments reported to CMS, 2019-2025
16 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,785 · 2020: $1,220 · 2021: $1,226 · 2022: $2,299 · 2023: $2,979 · 2024: $306 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,767 · Education: $7.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,766.57 |
| Education | $7.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,872.33 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $1,628.27 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $1,422.69 | 2019-2023 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $1,042.42 | 2019-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $916.16 | 2019-2022 | |
| Abbvie INC. | $786.18 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $643.69 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $527.68 | 2019-2023 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $494.18 | 2020-2024 | Caplyta |
| Lundbeck LLC | $338.72 | 2019-2023 | Rexulti |
| Allergan, INC. | $276.28 | 2019-2020 | |
| Indivior INC. | $164.13 | 2019-2023 | Perseris |
| Axsome Therapeutics, INC. | $114.30 | 2023 | Auvelity |
| Noven Therapeutics, LLC | $29.61 | 2020 | |
| Corium, LLC | $23.95 | 2023 | Adlarity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $23.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederic Monosiet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.